Bansal G P, Hatfield J A, Dunn F E, Kramer A A, Brady F, Riggin C H, Collett M S, Yoshimoto K, Kajigaya S, Young N S
MedImmune, Inc., Gaithersburg, MD 20878.
J Infect Dis. 1993 May;167(5):1034-44. doi: 10.1093/infdis/167.5.1034.
Recombinant baculoviruses were used to produce human B19 parvovirus empty capsids composed of only VP2 and VP2 capsids containing 4%, 25%, 35%, or 41% VP1 protein. Immunogenicity of the purified capsids, formulated with or without adjuvant, was evaluated in mice, guinea pigs, and rabbits. Sera were analyzed for total anti-B19 parvovirus antibodies, antibodies specific to the region unique to the VP1 capsid protein, and virus neutralizing antibodies. A relationship was observed between the development of antibodies specific to sequences unique to the VP1 protein and virus neutralization. The polypeptide composition of the empty capsid immunogens appeared to be important for elicitation of potent virus neutralizing activity. VP2 capsid immunogens devoid of VP1 protein, or consisting of only 4% VP1, the composition of naturally occurring virions, were generally poor at eliciting high levels of virus neutralizing activity. Capsids consisting of > or = 25% VP1 protein efficiently and consistently provoked vigorous B19 virus neutralizing responses. Recombinant empty capsids enriched for the VP1 protein should serve as the basis for a human B19 parvovirus vaccine.
重组杆状病毒被用于生产仅由VP2组成的人细小病毒B19空衣壳以及含有4%、25%、35%或41% VP1蛋白的VP2衣壳。纯化后的衣壳，无论是否添加佐剂，其免疫原性均在小鼠、豚鼠和兔子身上进行了评估。分析血清中的总抗细小病毒B19抗体、针对VP1衣壳蛋白独特区域的特异性抗体以及病毒中和抗体。观察到针对VP1蛋白独特序列的特异性抗体的产生与病毒中和之间存在关联。空衣壳免疫原的多肽组成对于引发有效的病毒中和活性似乎很重要。不含VP1蛋白或仅含4% VP1（天然存在的病毒粒子的组成）的VP2衣壳免疫原，通常难以引发高水平的病毒中和活性。由≥25% VP1蛋白组成的衣壳能够有效且持续地激发强烈的细小病毒B19中和反应。富含VP1蛋白的重组空衣壳应可作为人细小病毒B19疫苗的基础。
